Investing in Vical Incorporated (BBI)  ➔  Intrinsic value

Prev. close$0.90 
ModelValueUpside
Chepakovich$0.15-83%
Graham-Dodd$0.00-100%
Graham$35.40+3,848%
Previous Close$0.90  
Valuation MethodValuePotential 
Chepakovich Model$0.15-83%recalculate
Graham-Dodd$0.00-100%recalculate
Graham Formula$35.40+3,848%recalculate

Latest news

Company description

Brickell Biotech, Inc., a clinical-stage pharmaceutical company, focuses on identifying, developing, and commercializing various prescription therapeutics for the treatment of debilitating skin diseases in the United States. The company's lead product candidate is sofpironium bromide that is in phase 3 clinical trial to treat patients with primary axillary hyperhidrosis. Its pipeline consists of potential novel therapeutics for hyperhidrosis and other prevalent dermatological conditions. Brickell Biotech, Inc. has a collaboration agreement with AnGes, Inc. for the development of a novel DNA vaccine candidate for COVID-19. The company was founded in 2009 and is headquartered in Boulder, Colorado.